Expertise
Viral vector development for gene delivery/gene therapy
Our Measles-derived Virosomes can be used as a Adeno/AAV viral vectors
CEO
SAGITTA BIOTECH
Liège, Liège, Belgium
Sagitta Biotech is a company developing vaccines, oncology and gene therapy products from an hybrid Viral Vector/mRNA plaftorm
Develops innovative vaccines against infectious diseases and cancer. A ground-breaking proprietary platform which is a hybrid between viral vectors and mRNA techs. The platform is using a highly modified measles-derived vector, capable of expressing up to 6 antigens on the surface of a virosome, but also capable of delivering a self-replicating mRNA into target cells.
My organisation
Sagitta Biotech is developing innovative therapies against infectious diseases and cancer based on its viral vector/mRNA platform.
Sagitta's innovative platform is based on a reverse-engineering of the Measles virus, able to express up to 6 different antigen on its surface (including affinity proteins to infect cells carrying specific markers) and to deliver a self-replicating RNA in the cells.
The technology is being used to develop multivalent vaccines, oncology products or gene therapy vectors. We are looking for partners to evaluate our technology as a way to modify cells in vitro or in vivo (CAR T cell generation in vivo).
Skills
Interests
Expertise
Viral vector development for gene delivery/gene therapy
Our Measles-derived Virosomes can be used as a Adeno/AAV viral vectors